ASH 2022 | When should patients with intermediate-risk AML be indicated for alloSCT?
Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, shares some results from a study which evaluated whether patients with intermediate-risk acute myeloid leukemia (AML) should be indicated for allogeneic stem cell transplant (alloSCT) at first complete remission (CR) or if alloSCT should be reserved until first relapse. The study found that overall survival (OS) was similar in both groups, and those who received chemotherapy consolidation were more likely to relapse but could be successfully salvaged with transplantation, while transplanted patients experienced higher toxicity. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS: Consultancy, Honoraria; Amgen: Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Servier: Consultancy; Jazz: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria.
